Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely ...

Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

INDIANAPOLIS (WISH) — It’s 2025 and many are pledging New Year’s resolutions for self-improvement, but the expectations you put on yourself can be adding to leftover stress from the holidays ...

THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adul… ...

However, side effects so bad people had to stop taking the drugs were rare. Retatrutide is currently being developed by Eli Lilly & Co., and is being tested in ongoing clinical trials. Researchers ...